All In Biotech

Drug Trial Radar · NCT07682337

Study of Single and Multiple Oral Doses of SCB0020160 in Healthy Adult Male Subjects

A First-in-Human, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Food Effect of SCB0020160 After Oral Administration in Healthy Adult Male Subjects

Last checked: Nov 20, 2026Latest source record: Jul 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

74

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Jun 1, 2027

Study completion Jul 1, 2027

Sponsor

Lead sponsor
SCBIO Inc.Industry
Sponsor type
Industry
First posted
Jul 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study aims to evaluate the safety, tolerability, pharmacokinetics, and food effect of a new investigational medicine called SCB0020160 in healthy adult men. This is the first time SCB0020160 will be administered to humans. Healthy adult men aged 18 to 65 years who meet the study eligibility criteria. Study details Participants will be randomly assigned to receive either SCB0020160 or placebo. The study includes single-dose and multiple-dose treatment periods, as well as an assessment of the effect of food on the absorption of SCB0020160. Participants will undergo safety assessments including physical examinations, vital signs, ECGs, blood and urine tests, and monitoring of adverse events. The study will also assess how SCB0020160 is processed by the body. There is no direct health benefit expected from participation. The results may help determine safe dose levels and support future clinical development of SCB0020160.

Conditions

  • Solid Tumor
  • Obesity
  • Idiopathic Pulmonary Fibrosis

Interventions

  • SCB0020160Drug

    Single and multiple oral doses of SCB0020160 administered under fasting conditions. A food-effect evaluation following a single oral dose will be conducted in Part A Cohort 4.

  • PlaceboDrug

    Matching placebo administered orally under the same dosing conditions as SCB0020160, including participation in the food-effect evaluation in Part A Cohort 4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and frequency of adverse events, adverse drug reactions, serious adverse events, and serious adverse drug reactionsTime frame: From first dose through Post-Study Visit (up to Day 33)
  2. For Physical examination to evaluate General AppearanceTime frame: From first dose through Post-Study Visit (up to Day 33)
  3. For Physical examination to evaluate HEENTTime frame: From first dose through Post-Study Visit (up to Day 33)
  4. For Physical examination to evaluate Neck (incl Thyroid & Nodes)Time frame: From first dose through Post-Study Visit (up to Day 33)
  5. For Physical examination to evaluate CardiovascularTime frame: From first dose through Post-Study Visit (up to Day 33)
  6. For Physical examination to evaluate RespiratoryTime frame: From first dose through Post-Study Visit (up to Day 33)
  7. For Physical examination to evaluate GastrointestinalTime frame: From first dose through Post-Study Visit (up to Day 33)
  8. For Physical examination to evaluate RenalTime frame: From first dose through Post-Study Visit (up to Day 33)
  9. For Physical examination to evaluate NeurologicalTime frame: From first dose through Post-Study Visit (up to Day 33)
  10. For Physical examination to evaluate MusculoskeletalTime frame: From first dose through Post-Study Visit (up to Day 33)
  11. For Physical examination to evaluate SkinTime frame: From first dose through Post-Study Visit (up to Day 33)
  12. For Vital signs (body temperature (tympanic)Time frame: From first dose through Post-Study Visit (up to Day 33)
  13. For Vital signs (Pulse Rate)Time frame: From first dose through Post-Study Visit (up to Day 33)
  14. For Vital signs (Systolic/Diastolic blood pressure)Time frame: From first dose through Post-Study Visit (up to Day 33)
  15. For 12-lead ECG (electrocardiogram)Time frame: From first dose through Post-Study Visit (up to Day 33)
  16. For Clinical Laboratory Test which includes UrinalysisTime frame: From first dose through Post-Study Visit (up to Day 33)
  17. For Clinical Laboratory Test which includes the CoagulationTime frame: From first dose through Post-Study Visit (up to Day 33)
  18. For Clinical Laboratory Test which includes the Blood chemistryTime frame: From first dose through Post-Study Visit (up to Day 33)
  19. For Clinical Laboratory Test which includes the HematologyTime frame: From first dose through Post-Study Visit (up to Day 33)
  20. Pharmacokinetic Parameters of SCB0020160 for CmaxTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
  21. Pharmacokinetic Parameters of SCB0020160 for TmaxTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
  22. Pharmacokinetic Parameters of SCB0020160 for AUClastTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
  23. Pharmacokinetic Parameters of SCB0020160 for AUCinfTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
  24. Pharmacokinetic Parameters of SCB0020160 for t½Time frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
  25. Pharmacokinetic Parameters of SCB0020160 for CL/FTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
  26. Pharmacokinetic Parameters of SCB0020160 for Vz/FTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort
  27. Pharmacokinetic Parameters of SCB0020160 for MRTTime frame: Up to Day 8 (Part A), Up to Day 21 (Part B), and Up to Day 29 for the Food Effect Cohort

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CMAX Clinical Research Pty Ltd Ground Floor, 21-24 North Terrace

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.